Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives

Table 3

Graded risk reduction by ezetimibe therapy with absolute number of biomarkers elevated in substudy of the IMPROVE-IT trial. Modified from Qamar et al. [36] (NNT- number needed to treat).

Risk category	Number of biomarkers elevated	Absolute risk difference (%)	NNT
High risk	>3	−7.3	14
Intermediate risk	1-2	−4.4	23
Low risk	0	+3.0	—